Infantile pemphigoid treated without oral corticosteroids

Abstract

The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne) 2018; 5: 220. 2 Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients.

Pemphigoid diseases in infancy and childhood. A review of the literature

“…Jedną z proponowanych opcji leczenia IBP jest połączenie silnego miejscowego glikokortykosteroidu i erytromycyny stosowanej doustnie [19]. W piśmiennictwie dostępne są opisy przypadków IBP skutecznie leczonych dożylną terapią immunoglobulinami (intravenous immunoglobulin -IVIG).…”

“…One proposed treatment option for IBP is a combination of a potent topical glucocorticosteroids and oral erythromycin [19]. In the literature there are available cases of IBP successfully treated with intravenous immunoglobulin therapy (IVIG therapy), which could be considered as a possible treatment for patients resistant to conventional glucocorticosteroid therapy [20].…”

Macrolides for the treatment of bullous pemphigoid

“…However, none achieved remission via macrolide monotherapy; instead, macrolides were used in conjunction with topical corticosteroids, systemic corticosteroids, nicotinamide, and ranitidine [2 5]. In two patients, macrolides and topical/systemic corticosteroid combination therapy were used as initial treatment [2,5], whereas two others were given macrolides as corticosteroid-sparing agents following failure to control BP using initial corticosteroid therapy or corticosteroid with antibiotic combination therapy [3,4].…”